Companies › Daewoong Pharmaceutical
7 active drug programs in 12 registered trials: 11 Phase 1, 1 Phase 2; Other, Metabolic and endocrine, Respiratory, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DWN12088 | – | Phase 2 | Idiopathic Pulmonary Fibrosis | Jan 2027 |
| DWRX5003 GLP-1 receptor agonist delivered via microneedle patch | GLP1R | Phase 1 | Obesity & Overweight | Nov 2026 |
| DWP212525 | – | Phase 1 | Autoimmune Diseases | Dec 2026 |
| Olaparib (DWZ2501) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Cancer | Mar 2027 |
| DWC202313 | – | Phase 1 | Healthy Volunteers | – |
| DWJ1511 | – | Phase 1 | Healthy Subjects | – |
| DWJ1622 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07144176 | DWJ1511 | Phase 1 | Healthy Subjects | Other | Sep 2025 |
| NCT07260851 | DWJ1622 | Phase 1 | Healthy Volunteers | Other | Jan 2026 |
| NCT07267221 | DWJ1622 | Phase 1 | Healthy Volunteers | Other | Jan 2026 |
| NCT07260851 | DWC202313 | Phase 1 | Healthy Volunteers | Other | Jan 2026 |
| NCT07260851 | DWC202313 | Phase 1 | Healthy Volunteers | Other | Jan 2026 |
| NCT07267221 | DWC202313 | Phase 1 | Healthy Volunteers | Other | Jan 2026 |
| NCT07267221 | DWC202313 | Phase 1 | Healthy Volunteers | Other | Jan 2026 |
| NCT07539415 | DWRX5003 | Phase 1 | Obesity & Overweight | Metabolic and endocrine | Nov 2026 |
| NCT06736587 | DWP212525 | Phase 1 | Autoimmune Diseases | Immunology | Dec 2026 |
| NCT05389215 | DWN12088 | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Jan 2027 |
| NCT07371104 | Olaparib (DWZ2501) | Phase 1 | Cancer | Oncology | Mar 2027 |
| NCT07371104 | Olaparib (DWZ2501) | Phase 1 | Cancer | Oncology | Mar 2027 |
AstraZeneca Eli Lilly Novo Nordisk Merck & Co. (MSD) Roche Pfizer Hangzhou Sciwind Biosciences pharmaand Boryung Pharmaceutical Hangzhou Zhongmei Huadong Pharmaceutical
Yuhan Beijing QL Biopharmaceutical Basilea Pharmaceutica Shanghai Argo Biopharmaceutical Shanghai Minwei Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.